Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review

Bibliography

• Solon EG. Autoradiography: high resolution molecular imaging in pharmaceutical discovery and development. Expert Opin Drug Discov 2007;2(4):503-14
   PubMed Web of Science ®Google Scholar
• Shigematsu A, Motoji N, Hatori A, Satoh T. Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Regul Toxicol Pharmacol 1995;22:122-42
   PubMed Web of Science ®Google Scholar
• Braggio S, Montanari D, Rossi T, Ratti E. Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 2010;5(7):609-18
   PubMed Web of Science ®Google Scholar
• Cazzola M, Blasi F, Terzano C, Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am J Respir Med 2002;1(4):261-72
   PubMedGoogle Scholar
• Palmer GM, Boruta RJ, Viglianti BL, Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release 2010;142(3):457-64
   PubMed Web of Science ®Google Scholar
• Monro AM. Are routine tissue distribution studies justifiable for approval of human drugs? Drug Metab Dispos 1994;22(3):341
   PubMed Web of Science ®Google Scholar
• Monro AM. Interspecies comparison in toxicology: the utility and futility of plasma concentrations of the test substance. Regul Toxicol Pharmacol 1990;12:137-60
   PubMed Web of Science ®Google Scholar
• Brockman AH, Hatsis P, Paton M, Wu JT. Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. Anal Chem 2007;79:1599-603
   PubMed Web of Science ®Google Scholar
• Srinivas NR. Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon? Biomed Chromatogr 2009;23:447-9
   PubMed Web of Science ®Google Scholar
• James CA, Breda M, Baratte S, Analysis of drugs and metabolites in tissues and other solid matrices. Chromatogr Suppl 2004;59:S149-56
   Web of Science ®Google Scholar
• Drexler DM, Garrett TJ, Cantone JL, Utility of imaging mass spectrometry (IMS) by matrix assisted laser desorption ionisation (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J Pharmacol Toxicol Methods 2007;55:279-88
   PubMedGoogle Scholar
• Solon EG, Schweitzer A, Stoeckli M, Prideaux B. Autoradiography, MALDI –MS, and SIMS-MS imaging in pharmaceutical discovery and development. AAPS J 2010;12(1):11-26
   PubMed Web of Science ®Google Scholar
• Sugiura Y, Setou M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 2010;5:31-43
   PubMed Web of Science ®Google Scholar
• Heeren RMA, Smith DF, Stauber J, Imaging mass spectrometry: hype or hope? J Am Soc Mass Spectrom 2009;20(6):1006-14
   PubMed Web of Science ®Google Scholar
• Stumpf WE. Drug localisation and targeting with receptor microscopic autoradiography. J Pharmacol Toxicol Methods 2005;51:25-40
   PubMedGoogle Scholar
• Espie P, Tytgat D, Sargentini-Maier ML, Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 2009;41(3):391-407
   PubMed Web of Science ®Google Scholar
• Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J 2009;11(1):155-66
   PubMed Web of Science ®Google Scholar
• Fenneteau F, Turgeon J, Couture L, Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modelling: model structure and parameters determination. Theor Biol Med Model 2009;6(2):1-13
   PubMedGoogle Scholar
• Lanao JM, Fraile MA. Drug tissue distribution: study methods and therapeutic implications. Curr Pharm Des 2005;11:3829-45
   PubMed Web of Science ®Google Scholar
• Langer O, Muller M. Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 2004;5:463-81
   PubMed Web of Science ®Google Scholar
• Note for guidance for repeated dose tissue distribution studies. ICH topic S3B. CPMP/ICH/385/95. (1995). The European Agency for the Evaluation of Medicinal Products. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000396.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002956e
   Google Scholar
• Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab 2006;7:39-65
   PubMed Web of Science ®Google Scholar
• The International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-34
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000;355:979-82
   PubMed Web of Science ®Google Scholar
• Ahmad M, Ahmadi M, Nicholls J, Smith HJ. In-vitro metabolism of retinoic acid by different tissues from male rats. J Pharm Pharmacol 2000;52:511-15
   PubMed Web of Science ®Google Scholar
• Brocks DR, Mehvar R. Rate and extent of drug accumulation after multiple dosing revisited. Clin Pharmacokinet 2010;49(7):421-38
   PubMed Web of Science ®Google Scholar
• Hebb JH, Caplan YH, Crooks CR, Mergner WJ. Blood and tissue concentrations of tricyclic antidepressant drugs in post-mortem cases: literature survey and a study of forty deaths. J Anal Toxicol 1982;6:209-16
   PubMed Web of Science ®Google Scholar
• Drummer OH, Gerostamoulos J. Postmortem drug analysis: analytical and toxicological aspects. Ther Drug Monit 2002;24(2):199-209
   PubMed Web of Science ®Google Scholar
• Drummer OH. Requirements for bioanalytical procedures in post-mortem toxicology. Anal Bioanal Chem 2007;388:1495-503
   PubMed Web of Science ®Google Scholar
• Ferner RE. Post-mortem clinical pharmacology. Br J Clin Pharmacol 2008;66(4):430-43
   PubMed Web of Science ®Google Scholar
• Swanson JR, Jones GR, Krasselt W. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 1997;42(2):335-9
   PubMed Web of Science ®Google Scholar
• Eichler HG, Muller M. Drug distribution: the forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998;34(2):95-9
   PubMed Web of Science ®Google Scholar
• Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 2009;18(12):1843-64
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Apornwirat W, Shaharyar A, Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009;27:5363-9
   PubMed Web of Science ®Google Scholar
• Khojasteh A, Khojasteh A, Thornburg BG, Maher KR. Casopitant: a new warrior in the antiemetic crusade. Expert Opin Pharmacother 2009;10(8):1367-76
   PubMed Web of Science ®Google Scholar
• Miraglia L, Pagliarusco S, Bordini E, Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats and dogs. Drug Metab Dispos 2010;37:1876-91
   Google Scholar
• Casartelli A, Lanzoni A, Comelli R, A novel and integrated approach for the identification and characterisation of drug induced cardiac toxicity in the dog. Toxicol Pathol (In press)
   Google Scholar
• Pagliarusco S, Martinucci S, Bordini E, Tissue distribution and characterization of drug related material in rats and dogs after repeat oral administration of casopitant. Drug Metab Dispos 2010: Published ahead of print October 26, 2010, doi: 10.1124/dmd.110.035063
   Google Scholar
• Leblanc B, Jezequel S, Davies T, Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 1998;28:124-32
   PubMed Web of Science ®Google Scholar
• Muhlebach S, Moor MJ, Wyss PA, Bickel MH. Kinetics of distribution and elimination of DDE in rats. Xenobiotica 1991;21(1):111-20
   PubMed Web of Science ®Google Scholar
• Rogan WJ, Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT). Lancet 2005;366:763-73
   PubMed Web of Science ®Google Scholar
• Reasor MJ, Hastings KL, Ulrich RG. Drug- induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006;5(4):567-83
   PubMed Web of Science ®Google Scholar
• Gaertner HG, Liomin G, Villumsen D, Tissue metabolites of trifluoroperazine, fluphenazine, prochlorperazine and perphenazine. Kinetics in chronic treatment. Drug Metab Dispos 1975;3(6):437-43
   PubMed Web of Science ®Google Scholar
• Breyer U, Gaertner HJ. The phenotiazines and structurally related drugs. Raven Press, New York; 1974. p. 167-73
   Google Scholar
• Hein L, Lullmann-Rauch R, Mohr K. Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis. Xenobiotica 1990;20(11):1259-67
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Alvarez JC, Leenhardt A, Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol 2009;67(5):511-19
   PubMed Web of Science ®Google Scholar
• Adams PC, Holt DW, Storey GCA, Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985;72(5):1064-75
   PubMed Web of Science ®Google Scholar
• Gum RJ, Hickman D, Fagerland JA, Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem Pharmacol 2001;62:1661-73
   PubMed Web of Science ®Google Scholar
• Kim KY, Lee YJ, Chung BC, Relations between toxicity and altered tissue distribution and urinary excretion of nicotine, cotinine and hydroxycotinine after chronic oral administration of nicotine in rats. Drug Chem Toxicol 2010;33(2):166-72
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Hanasono GK, Miller WM, Wood PG. Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes. Xenobiotica 1987;17(4):459-68
   PubMed Web of Science ®Google Scholar
• Riley RT, Voss KA. Differential sensitivity of rat kidney and liver to fumonisin toxicity: organ- specific differences in toxin accumulation and sphingoid base metabolism. Toxicol Sci 2006;92(1):335-45
   PubMed Web of Science ®Google Scholar
• Hawkins E. Ototoxic mechanisms: a working hypothesis. Audiology 1973;12(5-6):383-93
   PubMedGoogle Scholar
• Kitasako I, Yokota M, Inouye S, Igarashi M. Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs. Chemother 1990;36(2):155-68
   PubMed Web of Science ®Google Scholar
• Dulon D, Aran JM, Zajic G, Schacht J. Comparative uptake of gentamicin, netilmicin and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 1986;30(1):96-100
   PubMed Web of Science ®Google Scholar
• Lin CJ, Wu MH, Hsueh YM, Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue selective. Cancer Chemother Pharmacol 2005;55:170-8
   PubMed Web of Science ®Google Scholar
• Park BK, Srivastava A, Maggs JL, Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol 2010;196:165-94
   PubMedGoogle Scholar
• Kumar S, Mitra K, Kassahun K, Baillie TA. Approaches for minimizing metabolic activation of new drug candidates in drug discovery. Handb Exp Pharmacol 2010;196:511-44
   PubMedGoogle Scholar
• Oitate M, Hirota T, Takahashi M, Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J Pharmacol Exp Ther 2007;320(3):1195-203
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol 2006;217:143-52
   PubMed Web of Science ®Google Scholar
• Williams RT. Detoxication mechanisms. John Wiley and Sons, Inc., New York; 1947
   Google Scholar
• Andersen ME, Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci 2009;107(2):324-30
   PubMed Web of Science ®Google Scholar
• Vonderfecht SL, Stone ML, Eversole RR, Myopathy related to administration of cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol 2004;32:318-25
   PubMed Web of Science ®Google Scholar
• Dear GJ, Roberts AD, Beaumont C, North S. Evaluation of preparative high performance liquid chromatography and cryoprobe- nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J Chromatogr B 2008;876:182-90
   PubMed Web of Science ®Google Scholar
• Espina R, Yu L, Wang J, Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem Res Toxicol 2009;22:299-310
   PubMed Web of Science ®Google Scholar
• Walker R. The significance of excursions above the ADI: duration in relation to pivotal studies. Regul Toxicol Pharmacol 1999;30:S114-18
   PubMed Web of Science ®Google Scholar